RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
ZacksRocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.